- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia or small lymphocytic lymphoma
- Meeting Date: December 2022
- Public Summary Document (PSD) December 2022 PBAC Meeting - (PDF 991KB)
- Public Summary Document (PSD) December 2022 PBAC Meeting - (Word 375KB)
Ibrutinib – December 2022
Ibrutinib: Capsule 140 mg; Imbruvica® – December 2022
Last updated
21 April 2023